Diabète De Type 2

Diabète de type 1 : tous dans les starting blocks pour changer le cours de la maladie.

L'immunité au coeur des diabètes : un aspect central de la SFD 2024.

Focus sur la cellule beta / exploration de la pathogenèse du diabète.

Practical Guidance based on the 2022 ADA/EASD Guidelines.

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.¹

Summary of The UK Prospective Diabetes Study (UKPDS).

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.

Trouvez ici toutes les informations et le soutien pour vous et vos patients diabétiques qui choisissent de jeûner pendant le Ramadan.

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.